THE CHALLENGES AND OPPORTUNITIES OF DRUG DELIVERY THROUGH A COMPLEX BARRIER
Jon Volmer, Marc Brown and Jeremy Drummond discuss the development and use of advanced
models for testing new ocular medicines to meet a growing unmet need.
TARGETING DRUGS TO DISEASED OCULAR CELLS
Frazer Coutinho, Colin Green and Ilva Rupenthal discuss the targeted delivery of ocular therapeutics to diseased cells, using the cell-penetrating peptide, Xentry.
USING MARKET RESEARCH TO CREATE A PRESERVATIVE-FREE MULTIDOSE EYEDROPPER
Thomas Grinnan and Ralf Hergenröther explain how extensive market research and consumer testing led to the development of an eyedropper that meets patients’ and physicians’ needs for an easy-to-use device, which offers precise dosing and anti-microbial integrity.
USER TESTING: CRITICAL FOR TRULY UNDERSTANDING PATIENT NEEDS
Fanny Sellier presents a trio of comparative user studies between Nemera’s Novelia
preservative-free, multidose eyedropper and similar products from competitors
Dr Gautam N Shetty
Congruence Medical Solutions
ACCURATE, PRECISE MICROLITRE DOSING WITH PREFILLABLE SYRINGES FOR OPHTHALMIC INJECTIONS
Gautam Shetty discusses the challenges inherent to delivering microlitre dosage volumes accurately from a standard prefilled syringe, and introduces Congruence’s Microlitre Dosing Syringe (MDS) platform as a solution.
Dr Christian Roesky
BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE
Christian Roesky discusses the underserved condition of dry eye disease, and presents two products in Novaliq’s pipelinefor the treatment of different types of DED.
KEEPING PRESERVATIVE-FREE EYEDROPS STERILE WITH THE STERIDROP™ TUBE
Ralf Künzi introduces the SteriDrop™ tube – a new multidose eyedrop delivery solution made in collaboration with Aptar Pharma.
INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS
With the increasing use of intravitreal injections of vascular endothelial growth factor inhibitors in the treatment of numerous serious ocular diseases, Douglas Cusato provides a detailed comparative analysis of the issues at play.
Dr Peter Noymer
ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA
Peter Noymer, Ehud Ivri, Reynaldo Quintana and Mark Blumenkranz introduce AcuStream, a novel device for next-generation delivery of topical ophthalmic delivery via an aim-assisted stream.
TRENDS IN ANTI-GLAUCOMA TOPICAL TREATMENTS
Rouven Kraus presents the case for multidose delivery systems rather than single-use disposables, and introduces Aero Pump’s Ophthalmic Multidose System.
EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY
Nemera introduces the e-Novelia® and e-Advancia® add-ons for ophthalmic and nasal devices.
AN OPTIMISED PLATFORM FOR HIGHLY SENSITIVE BIOLOGICS
Alessio Bonati discusses the problematic interactions between drugs and their primary containers and goes on to introduce the Alba platform, Ompi’s range of primary glass containers designed to unify drug-container interactions over a product’s lifecycle.
Dr Shikha P Barman
SUSTAINED DRUG DELIVERY TO THE POSTERIOR SEGMENTS OF THE EYE
Shikha Barman reviews approaches for delivering drugs for diseases of the back of the eye, and introduces EySite-InjecT
FANNY SELLIER, NEMERA
Talking here with ONDrugDelivery Magazine, Ms Sellier discusses Nemera’s multidose eyedropper system Novelia® for preservative-free formulations. She explains how this platform has been developed to improve patients’ lives.
Dr Christian Roesky
AQUEOUS-FREE OPHTHALMIC DELIVERY TECHNOLOGY
Traditional aqueous vehicles for topical ophthalmic medications suffer from a number of limitations. Christian Roesky reviews the benefits of EyeSol®, a proprietary aqueous-free drug delivery technology.
Dr Paul Kippax
PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS
Here, Paul Kippax describes the methods by which bioequivalence can be established for ophthalmic microemulsions by in vitro testing, saving the need for costly clinical trials.
USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY
Di Huang, Erica Chen and Ilva Rupenthal discuss the possibilities offered by physical force-based methods of enhancing the efficacy of ophthalmic drug delivery by providing a way past the eye’s natural barriers.
SUSTAINED RELEASE OCULAR THERAPEUTICS
Michael O’Rourke gives an overview of the current state of the ophthalmics market, going into greater detail on the opportunities offered in the area of sustained-release technologies and therapies.
Dr Raj Thakur
BIODEGRADABLE IMPLANTS FOR SUSTAINED INTRAOCULAR DELIVERY
Raj Thakur and Prof David Jones discuss the difficulty of treating diseases of the back and front of the eye, and introduce a possible solution: OcuLief™ and EyeLief™, Re-Vana’s two proprietary sustained-release platforms.
Dr Patricia Zilliox
CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE
Patricia Zilliox discusses the inherent difficulties in drug delivery to the back of the eye and how this creates an unmet need in ophthalmology. Dr Zilliox goes on to describe Eyevensys’ novel solution to this problem, and the company’s first lead product, EYS606.
Anne Brody Rubin
A TOPICAL OCULAR RING DESIGNED TO REPLACE GLAUCOMA EYE DROPS
Anne Brody Rubin introduces ForSight VISION5's ring-shaped ocular insert containing prostaglandin for the lowering of intra-ocular pressure in glaucoma.
Dr Paul Seaman
OPSISPORIN: A LONG-ACTING DRUG DELIVERY APPROACH FOR UVEITIS
Here, Paul Seaman and Daniel Palmer discuss Midatech Pharma’s next generation treatments for auto-immune ocular diseases, which use a combination of innovative, sustained-release drug products.
Dr Mika Jokinen
NEW SOLUTIONS FOR OPHTHALMIC DRUG DELIVERY USING BIODEGRADABLE SILICA MATRIX
Mika Jokinen, Cora Griffin, and Lasse Leino, PhD describe the novel opportunities that biodegradable silica matrix technology offers to ophthalmic drug delivery.
Robin de Bruijn
IMPROVING OPHTHALMIC DRUG DELIVERY WITH NOVEL EMULSION TECHNOLOGIES
Robin de Bruijn and Frank de Jong describe EmulTech’s ET4ME micro-encapsulation process, and its suitability as a particle formation technology for enhancing and enabling ophthalmic injectables.
USING INTELLIGENT DESIGN TO DELIVER SAFE MULTI-DOSE EYE DROPS
Ms Fanny Sellier, explains how the intelligent design of multi-dose bottles provides a viable means of delivering safe, preservative-free eye drops.
SUSTAINED-RELEASE OCULAR DELIVERY TECHNOLOGIES
Michael O'Rourke discusses the advances in the development and launching of sustained-release ocular drug delivery systems seen in recent years.
Micro Engineering Solutions
SCALEABILITY OF MICRO INTRAOCULAR IMPLANTS AND DEVICES
Donna Bibber discusses some of these micro-intraocular implants and devices and the scalability challenges associated with each, from the perspective of a plastics engineer.
THERAPY WITHOUT DROPS: A REALITY
Chris Muller and Deepank Utkhede introduce Mati Therapeutics' Evolute
ocular delivery system, a non-invasive, sustained-release platform that combines a novel punctal plug with a sustained release drug eluting core.
Dr Shikha P Barman
INTRODUCING OCUSURF™ NANOSTRUCTURED EMULSION AS A 505(B)(2) STRATEGY
Shikha P Barman describes how Integral Biosystems is developing a series of ophthalmic products with its OcuSurf platform.
Dr Paul Ashton
PSIVIDA AND OPHTHALMIC DRUG DELIVERY
Paul Ashton describes how much of the progress that has been made recently in the treatment of ophthalmic diseases can be ascribed to effective drug delivery systems, and outlines some of the delivery technologies and resulting products for which pSivida has been responsible.
Dr Marc Horner
MODELLING OCULAR DELIVERY USING COMPUTATIONAL FLUID DYNAMICS
Paul Missel and Marc Horner describe the use of computational fluid dynamics simulations to predict drug flow and temperature inside the eye, and provide examples of applications modelling.
Dr Paul Ashton
HUGE THERAPEUTIC ADVANCES: BIGGER DRUG DELIVERY OPPORTUNITIES
Paul Ashton gives an introduction into the current state of the ophthalmics market.
Dr Dieter Scherer
AN INTEGRATED PIPELINE OF OPHTHALMIC PRODUCTS BASED ON EYESOL™ DELIVERY TECHNOLOGY
Dieter Scherer describes two of Novaliq’s most advanced products: NovaTears
, a wetting agent for the ocular surface, and CyclASol
, a clear formulation of Cyclosporin A. Both products use Novaliq’s semifluorinated alkane technology, EyeSol
Dr Ilva D Rupenthal
OCULAR DRUG DELIVERY TECHNOLOGIES: EXCITING TIMES AHEAD
Ilva Rupenthal gives a sector overview of the occular drug delivery space.
Dr Janice Cacace
EXCIPIENT SELECTION FOR OPHTHALMIC OINTMENTS
Janice Cacace and Travis Webb describe the physical properties of petrolatums as they relate to the comfort and efficacy of formulations of ophthalmic ointments.
COMPANY SHOWCASE: GRAYBUG
GrayBug is advancing ophthalmic therapeutics through a continuum of polymerbased drug delivery platforms and innovative products offering sustained competitive advantage.
CURRENT AND FUTURE OPHTHALMIC FORMULATION AND PROCESS DEVELOPMENT TRENDS
Brian McMillan provides some insights into his personal experiences in the development of ophthalmic products and the significant role of innovative delivery systems in improving efficacy and reducing side-effects.
Dr Daniel A Bernards
ZERO-ORDER SUSTAINED DRUG DELIVERY TO THE RETINA FROM A NANOPOROUS FILM DEVICE
Daniel Bernards, Robert Bhisitkul and Tejal Desai discuss the development of a nanoporous membrane-based implant which can significantly improve drug delivery to the back of the eye.
This website uses functional cookies (but not advertising cookies). View our
Privacy & Cookies Policy